Dr. Heschi Rotmensch serves as chief medical officer of CATO SMS. In this capacity, Rotmensch is responsible for the global medical affairs and pharmacovigilance departments.
Prior to his current role, Rotmensch served as senior vice president, drug development. In this capacity, he was responsible for ex-North America clinical trial operations at CATO Research Ltd. and oversaw the expansion of operations outside North America by applying his extensive clinical research experience in cardiovascular, neurology, and rare disease drug development. Prior to that he served as vice president, clinical research division Germany at Parexel International. Prior to joining the CRO industry, Rotmensch served as associate director of the division of clinical pharmacology at Merck Sharp & Dohme Research Laboratories and at the Jefferson Medical College in Philadelphia. Subsequently, Rotmensch was appointed chief of medicine at the Edith Wolfson Medical Center in Holon, Israel.
Rotmensch holds an M.D. degree from the Sackler Faculty of Medicine at the Tel-Aviv University and an MBA from the Kellogg-Recanati Faculty of Management. Rotmensch is board certified in internal medicine and clinical pharmacology and has published more than 90 research papers, including nine book chapters.